Fig. 7: The anti-CXCL16 mAb synergizes with imatinib to attenuate the progression of Ph⁺ B-ALL.

a Flow cytometric analysis of the percentages of B220^dim CD19⁺ cells in BM, spleens, LNs and PB of mice with secondary transplantation treated with or without rmCXCL16 (n = 6 mice per group). b–d Representative images of Wright-Giemsa-stained PB smears (b, top), H&E staining of spleens (b, bottom), spleens (c) and spleen weights (d) from the indicated mice (n = 6 mice per group). e Representative images of Ki67 staining in the spleen tissues from the indicated mice. n = 4 fields, two different mice per group. f Flow cytometric analysis of the percentages of Th17 cells in the PB, LNs, spleens and BM from the indicated mice (n = 6 mice per group). g Spleen tissues from the indicated mice were subjected to immunofluorescence staining for IL-17A (red), CD4 (green), and B220 (rose red). Representative images of Th17 cells were shown. n = 4 fields, two different mice per group. h Kaplan–Meier survival curves for the indicated mice (n = 8 mice per group). i Schematic strategy for investigating the effects of anti-CXCL16 mAb alone or combined with imatinib on Ph⁺ B-ALL progression. j–l Representative images of spleens (j), spleen weights (k), Wright-Giemsa-stained PB smears (l, top), and H&E staining of the spleen (l, bottom) from leukemia mice treated with the indicated agents (n = 3 mice per group). m Flow cytometric analysis of the percentages of B220^dim CD19⁺ cells in the PB, BM, LNs and spleens from leukemia mice treated with the indicated agents (n = 3 mice per group). n The percentage of Ki-67⁺ cells in the spleen was detected by immunofluorescence staining in the indicated mice. Data are presented as means ± S.E.M of eight random fields of view from three different mice per group. o Flow cytometric analysis of the percentages of Th17 cells in the PBMCs, LNs, spleens and BM of leukemia mice treated with the indicated agents (n = 3 mice per group). (a, m) The gating strategy for B220^dim CD19⁺ cells was shown in Supplementary Fig. 3a. (f, o) The gating strategy for Th17 cells in the CD4⁺ T cells was shown in Supplementary Fig. 6b. Statistical significance was calculated by (a, d–g) two-tailed Student’s t-test; (k, m–o) one-way ANOVA with Tukey’s multiple comparison tests; Data are presented as means ± S.E.M. Source data are provided as a Source Data file.